Prescription-Only Domperidone in an Older Adult with Heart Failure and CKD: A Cardiac Risk Review Case Study

Which cardiac patients with nausea should not receive domperidone in primary care?

Avoid domperidone in primary care if the cardiac patient has any known QT prolongation, history of ventricular arrhythmia, significant bradycardia, or structural/underlying cardiac disease such as heart failure or clinically important ischemic disease. Do not use it if they are also taking other QT-prolonging or potent

What baseline ECG and electrolyte abnormalities make domperidone unsafe?

Assuming adult use of domperidone and a baseline/risk-assessment question: Domperidone should generally be avoided if the baseline ECG shows QTc prolongation, especially QTc 450 ms in men or 470 ms in women, and it is high risk/usually contraindicated if QTc is ≥500 ms because of increased risk of torsades de pointes a

How should QTc, bradycardia, CKD, and CYP3A4 interactions be weighted before a short course of domperidone?

Assuming adult, non-pregnant outpatient use in the Philippines, the weighting before even a short course of domperidone should be: 1. CYP3A4 inhibitor or another QT-prolonging drug present = highest-weight / usually do not use domperidone 2. Baseline prolonged QTc or known cardiac conduction disease = highest-weight /

What antiemetic strategies are safer for older HF patients with polypharmacy and recurrent nausea?

Assuming an older adult with chronic HF, recurrent non-chemotherapy nausea, and significant polypharmacy in the Philippines. For older HF patients, the safest antiemetic approach is usually: - Treat the cause first: medication-related nausea, constipation, gastroparesis, uremia, hepatic congestion, reflux, infection, A

Does a normal baseline QTc meaningfully lower risk in HF and CKD, or should structural disease still favour avoidance?

Yes — a normal baseline QTc lowers observed immediate risk somewhat, but it does not neutralize risk in a patient with heart failure (HF) and chronic kidney disease (CKD). Structural/electrophysiologic substrate still matters, so if a drug has meaningful torsadogenic potential, HF and CKD should still push you toward a